Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 juin 2019 08h30 HE | Source: Eyenovia, Inc.

Eyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia

NEW YORK, June 04, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
14 mai 2019 06h30 HE | Source: Eyenovia, Inc.

Eyenovia Reports First Quarter 2019 Financial Results

NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented...
06 mai 2019 08h30 HE | Source: Eyenovia, Inc.

Eyenovia Announces Presentation of Successful Phase 3 Studies at the ASCRS-ASOA Annual Meeting

NEW YORK, May 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented...
01 mai 2019 08h30 HE | Source: Eyenovia, Inc.

Eyenovia Announces Conference Call and Webcast for First Quarter 2019 Financial Results

NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented...
27 mars 2019 06h30 HE | Source: Eyenovia, Inc.

Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results

NEW YORK, March 27, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
13 mars 2019 08h30 HE | Source: Eyenovia, Inc.

Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results

NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
04 mars 2019 08h30 HE | Source: Eyenovia, Inc.

Eyenovia to Participate in Two Upcoming Investor Conferences

NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
25 févr. 2019 08h30 HE | Source: Eyenovia, Inc.

Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis

MIST-2 study meets primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, good tolerability in confirmatory MIST-2 Study NEW YORK, Feb. 25, 2019 ...
13 févr. 2019 08h30 HE | Source: Eyenovia, Inc.

Eyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering

NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
06 févr. 2019 08h30 HE | Source: Eyenovia, Inc.

Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia

NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...

Page précédente